Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

A vizsgálat adatai

Ki végzi

Medtronic Cardiovascular

Azonosító

NCT02701283

A regiszteradat frissítve

2026. november 2.

Eredeti leírás

The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR.A teljes eredeti leírásKevesebb

Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement

The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR.

The purpose of the expanded use addendum to the Medtronic TAVR in Low Risk Patients Trial protocol is to conclude the randomized phase of the trial and initiate the single-arm, non-randomized, continued access phase of the trial.

Bevonási feltételek: Severe aortic stenosis, defined as follows:; For symptomatic patients:; Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean gradient ≥40 mmHg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest; For asymptomatic patients:; Very severe aortic stenosis with an aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec , or mean gradient ≥60 mmHg by transthoracic echocardiography at rest, OR; Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND a mean gradient ≥40 mmHg or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND an exercise tolerance test that demonstrates a limited exercise capacity, abnormal BP response, or arrhythmia OR; Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND mean gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND a left ventricular ejection fraction <50%; Documented heart team agreement of low risk for SAVR, where low risk is defined as predicted risk of mortality for SAVR <3% at 30 days per multidisciplinary local heart team assessment; The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

Kizáró feltételek: Any percutaneous coronary or peripheral interventional procedure with a bare metal stent within 30 days prior to randomization, or drug eluting stent performed within 180 days prior to randomization; Currently participating in an investigational drug or another device trial (excluding registries); Evidence of an acute myocardial infarction ≤30 days before the trial procedure due to unstable coronary artery disease (WHO criteria); Need for emergency surgery for any reason; Severe mitral regurgitation amenable to surgical replacement or repair; Severe tricuspid regurgitation amenable to surgical replacement or repair; Moderate or severe mitral stenosis amenable to surgical replacement or repair; Any condition considered a contraindication for placement of a bioprosthetic valve (eg, subject is indicated for mechanical prosthetic valve); A known hypersensitivity or contraindication to any of the following that cannot be adequately pre-medicated:; aspirin or heparin (HIT/HITTS) and bivalirudin; ticlopidine and clopidogrel; Nitinol (titanium or nickel); contrast media; Multivessel coronary artery disease with a Syntax score >22 and/or unprotected left main coronary artery; Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 10 weeks of Heart Team assessment; Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support; Recent (within 2 months of Heart Team assessment) cerebrovascular accident (CVA) or transient ischemic attack (TIA); Gastrointestinal (GI) bleeding that would preclude anticoagulation; Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits); Estimated life expectancy of less than 24 months due to associated non-cardiac co-morbid conditions; Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams; Pre-existing prosthetic heart valve in any position; Blood dyscrasias as defined: leukopenia (WBC <1000 mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states; Subject is less than legal age of consent, legally incompetent, or otherwise vulnerable; Ongoing sepsis, including active endocarditis; Subject refuses a blood transfusion; Subject is pregnant or breast feeding; Hypertrophic obstructive cardiomyopathy with left ventricular outflow gradient; Bicuspid aortic valve verified by echocardiography, MDCT, or MRI; Prohibitive left ventricular outflow tract calcification; Sinus of Valsalva diameter unsuitable for placement of the self-expanding bioprosthesis; Aortic annulus diameter of <18 or >30 mm; Significant aortopathy requiring ascending aortic replacement; For transfemoral or transaxillary (subclavian) access:; Access vessel mean diameter <5.0 mm for Evolut 23R, 26R, or 29R mm TAV, or access vessel mean diameter <5.5 mm for Evolut 34R mm or Evolut PRO TAV. However, for transaxillary (subclavian) access in patients with a patent LIMA, access vessel mean diameter <5.5mm for Evolut 23R, 26R, or 29R mm TAV, or access vessel mean diameter <6.0 mm for the Evolut 34R or Evolut PRO TAV.

ClinicalTrials.gov NCT02701283